Clinical Trials Browser

Interventional × bemarituzumab × 90 days × Clear all

Carcinoma, Renal Cell

NCT05052801 2026-02-19

FORTITUDE-101

Phase 3 Active not recruiting

547 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05325866 2026-02-04

FORTITUDE-301

Phase 1/2 Completed

260 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06967987 2026-01-21

BEMAFLOT

Phase 2 Withdrawn

Tumor-Agnostic

Adenocarcinoma

Clinical Trials

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

FORTITUDE-101

FORTITUDE-301

BEMAFLOT